Meiji holdings streamlines pharma operations, transfers KMB shares to MSP

Meiji Holdings has decided to transfer its 5,800 common shares of KM Biologics (KMB) to its consolidated subsidiary, Meiji Seika Pharma (MSP), through a short-form absorption-type company split. This move, approved on November 20, 2025, is scheduled to take effect on January 30, 2026. The objective is to strengthen the pharmaceutical segment's business foundation and accelerate new drug development, aligning with the "2026 Medium-Term Business Plan."

This internal restructuring will consolidate management policies and business strategies between MSP and KMB, promoting greater collaboration across the entire value chain from research and development to manufacturing and sales. Both companies specialize in infectious diseases, including vaccines and antibacterial drugs. There will be no allocation of new shares or monies, nor any change in the stated capital of Meiji Holdings as a result of this transaction.

The transfer is an internal group transaction, and Meiji Holdings anticipates a negligible impact on its consolidated financial results. For the fiscal year ending March 31, 2025, Meiji Holdings reported net sales of JPY 1,154,074 million and an ordinary profit of JPY 82,013 million. MSP reported net sales of JPY 155,506 million and an ordinary profit of JPY 6,416 million for the same period.